[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608952":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":53,"collaborators":30,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":30,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":30,"enrollmentInfo":65,"targetDuration":30,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Rabin Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients receiving Tb-PSMA before RAdical prostatectomy","EXPERIMENTAL","Patients with high-risk locally advanced prostate cancer will receive 3 Tb-161-PSMA treatments followed by radical prostatectomy.",[13],"Drug: Tb-PSMA-I&T (Tb-PSMA)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Tb-PSMA-I&T (Tb-PSMA)","Terbium-161 produce beta emission with the addition of Auger electrons which have higher linear energy transfer and a very short range. By that it has the potential to improve local and distal (micro-metastatic disease) efficacy with a similar safety profile. It will be given to patients with high risk locally advanced prostate cancer prior to Radical prostatectomy",[9],[21],"radical prostatectomy",[23],{"name":24,"affiliation":5,"role":25},"Shay Golan, MD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","+972507447573",null,"Shaygo1@gmail.com",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Hana Burnstein, MD","+972544400822","hanna@erezcom.net",[37],{"facility":38,"status":39,"city":40,"state":30,"zip":30,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Beilinson Hospital","RECRUITING","Petah Tikva","Israel","IL",{"type":44,"coordinates":45},"Point",[46,47],34.88747,32.08707,{"lat":47,"lon":46},[50],{"name":24,"role":28,"phone":51,"phoneExt":30,"email":52},"+97239376559","Shayg@clalit.org.il",{"type":25,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"golan shay","Pro Shay Golan , Chair of Urology at Rabin Medical Cener","100608952","phase-1-tb-psma-it-radionuclide-before-radical-prostatectomy-in-patients-with-locally-advanced-prostate-cancer---tbeforeprost-trial-100608952",false,"NCT07208240","Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.","Tb-PSMA-I&T Radionuclide Neo-Adjuvant Treatment in Patients With Locally Advanced Prostate Cancer Before Radical Prostatectomy: TbeforePROST Trial.","Inclusion Criteria:\n\n* Male aged 18 years and older.\n* Patients with high-risk localized prostate cancer (cT3\u002F4 and\u002For Gleason score ≥ eight and\u002For prostate biopsy or PSA ≥ 20 ng\u002Fdl)\n* High PSMA expression was confirmed according to PROMISE V2 8\n* Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status score of 1 or lower and a life expectancy of \\> 10 years.\n\nExclusion Criteria:\n\n* Platelet count lower than 150×103\u002Fµl\n* white blood cell count lower than 4×103\u002Fµl,\n* haemoglobin concentration lower than 12mg\u002Fdl.\n* albumin concentration lower than 3.5 g\u002Fdl.\n* glomerular filtration rate (GFR) lower than 40 mL\u002Fmin.\n* usage of nephrotoxic drugs\n* distant metastatic disease","MALE","18 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE1","PHASE2","This is a multi-disciplinary collaboration between urologists, oncologists and nuclear medicine physicians from Beilinson hospital at Rabin Medical Center to address the major therapeutic challenge of locally advanced prostate cancer. Our aim is to evaluate the use of a novel treatment (Tb-PSMA) prior to the surgical removal of the prostate. This treatment has already shown initial promising results in patients with metastatic prostate cancer but has never been tested for locally advanced disease before surgery.",[74],"High Risk Prostate Cancer",[76,77,78,79,80],"High risk Prostate cancer","Radical Prostatectomy","PSMA","Theranostics","radionuclide therapy","2025-09-26",{"date":83,"type":84},"2025-10-06","ACTUAL",{"date":86,"type":84},"2025-08-12",{"date":88,"type":67},"2028-08-12",{"name":5,"class":6},1]